The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Disis, M. L.
Right arrow Articles by Cheever, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Disis, M. L.
Right arrow Articles by Cheever, M. A.

The Journal of Immunology, Vol 156, Issue 9 3151-3158, Copyright © 1996 by American Association of Immunologists

ARTICLES

Peptide-based, but not whole protein, vaccines elicit immunity to HER- 2/neu, oncogenic self-protein

ML Disis, JR Gralow, H Bernhard, SL Hand, WD Rubin and MA Cheever
Department of Medicine, University of Washington, Seattle 98195, USA.

HER-2/neu, an overexpressed oncogenic protein, has been proposed as a human cancer vaccine target. HER-2/neu is a "self" protein, however, and methods of vaccine strategies that would be effective in immunizing patients to a "self" tumor Ag have not been established. Many of the tumor Ags defined in humans are nonmutated self proteins, e.g., MAGE, and overcoming tolerance may be key in the generation of effective anti- tumor immunity. One theory states that tolerance to self proteins is directed only to dominant epitopes of proteins and not to every portion of the protein. Accordingly, tolerance can be circumvented by immunization to peptide fragments, but not whole protein. The studies outlined here demonstrate rat neu-specific immunity could be elicited in rats by vaccination with immunogenic rat neu peptides, but not by immunization with the intact protein. A rat model was used since rat neu protein is 89% homologous to human HER-2/neu protein and has a similar tissue distribution and level of expression. Rats were immunized with groups of peptides derived from the amino acid sequence of the intracellular domain or extracellular domain of rat neu protein and both groups developed CD4+ T cell immunity and Ab immunity to rat neu peptides and protein. Animals immunized in a similar fashion with intact purified rat neu protein did not develop Ab or T cell immunity to rat neu. Furthermore, rats that developed neu-specific immunity showed no histopathologic evidence of autoimmunity directed against organs expressing basal levels of rat neu protein. These studies suggest an immunization strategy that might be effective in human cancer vaccines targeting self tumor Ag.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
H. Li, P. C. Chien Jr., M. Tuen, M. L. Visciano, S. Cohen, S. Blais, C.-F. Xu, H.-T. Zhang, and C. E. Hioe
Identification of an N-Linked Glycosylation in the C4 Region of HIV-1 Envelope gp120 That Is Critical for Recognition of Neighboring CD4 T Cell Epitopes
J. Immunol., March 15, 2008; 180(6): 4011 - 4021.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. Li, S. Andreansky, G. Helguera, M. Sepassi, N. Janikashvili, J. Cantrell, C. L. LaCasse, N. Larmonier, M. L. Penichet, and E. Katsanis
A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model
Mol. Cancer Ther., March 1, 2008; 7(3): 721 - 729.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. D. Allen, J. T. Garrett, S. V. Rawale, A. L. Jones, G. Phillips, G. Forni, J. C. Morris, R. G. Oshima, and P. T. P. Kaumaya
Peptide Vaccines of the HER-2/neu Dimerization Loop Are Effective in Inhibiting Mammary Tumor Growth In Vivo
J. Immunol., July 1, 2007; 179(1): 472 - 482.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. T. Garrett, S. Rawale, S. D. Allen, G. Phillips, G. Forni, J. C. Morris, and P. T. P. Kaumaya
Novel Engineered Trastuzumab Conformational Epitopes Demonstrate In Vitro and In Vivo Antitumor Properties against HER-2/neu
J. Immunol., June 1, 2007; 178(11): 7120 - 7131.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. O'Mahony, S. Kummar, and M. E. Gutierrez
Non-Small-Cell Lung Cancer Vaccine Therapy: A Concise Review
J. Clin. Oncol., December 10, 2005; 23(35): 9022 - 9028.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
F. Rohrbach, R. Weth, M. Kursar, A. Sloots, H.-W. Mittrucker, and W. S. Wels
Targeted Delivery of the ErbB2/HER2 Tumor Antigen to Professional APCs Results in Effective Antitumor Immunity
J. Immunol., May 1, 2005; 174(9): 5481 - 5489.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. K. Dakappagari, K. D. Lute, S. Rawale, J. T. Steele, S. D. Allen, G. Phillips, R. T. Reilly, and P. T. P. Kaumaya
Conformational HER-2/neu B-cell Epitope Peptide Vaccine Designed to Incorporate Two Native Disulfide Bonds Enhances Tumor Cell Binding and Antitumor Activities
J. Biol. Chem., January 7, 2005; 280(1): 54 - 63.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Takeuchi, S.-i. Hiraoka, X.-Y. Zhou, M. Nagafuku, S. Ono, T. Tsujimura, M. Nakazawa, Y. Yura, T. Hamaoka, and H. Fujiwara
Anti-HER-2/neu Immune Responses Are Induced before the Development of Clinical Tumors but Declined following Tumorigenesis in HER-2/neu Transgenic Mice
Cancer Res., October 15, 2004; 64(20): 7588 - 7595.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. B. Riemer, M. Klinger, S. Wagner, A. Bernhaus, L. Mazzucchelli, H. Pehamberger, O. Scheiner, C. C. Zielinski, and E. Jensen-Jarolim
Generation of Peptide Mimics of the Epitope Recognized by Trastuzumab on the Oncogenic Protein Her-2/neu
J. Immunol., July 1, 2004; 173(1): 394 - 401.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. L. Disis, K. Schiffman, K. Guthrie, L. G. Salazar, K. L. Knutson, V. Goodell, C. dela Rosa, and M. A. Cheever
Effect of Dose on Immune Response in Patients Vaccinated With an HER-2/neu Intracellular Domain Protein--Based Vaccine
J. Clin. Oncol., May 15, 2004; 22(10): 1916 - 1925.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. L. Disis, N. Scholler, A. Dahlin, J. Pullman, K. L. Knutson, K.-E. Hellstrom, and I. Hellstrom
Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity
Mol. Cancer Ther., October 1, 2003; 2(10): 995 - 1002.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
V. Renard, L. Sonderbye, K. Ebbehoj, P. B. Rasmussen, K. Gregorius, T. Gottschalk, S. Mouritsen, A. Gautam, and D. R. Leach
HER-2 DNA and Protein Vaccines Containing Potent Th Cell Epitopes Induce Distinct Protective and Therapeutic Antitumor Responses in HER-2 Transgenic Mice
J. Immunol., August 1, 2003; 171(3): 1588 - 1595.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. K. Dakappagari, J. Pyles, R. Parihar, W. E. Carson, D. C. Young, and P. T. P. Kaumaya
A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses
J. Immunol., April 15, 2003; 170(8): 4242 - 4253.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Schlienger, C. S. Chu, E. Y. Woo, P. M. Rivers, A. J. Toll, B. Hudson, M. V. Maus, J. L. Riley, Y. Choi, G. Coukos, et al.
TRANCE- and CD40 Ligand-matured Dendritic Cells Reveal MHC Class I-restricted T Cells Specific for Autologous Tumor in Late-Stage Ovarian Cancer Patients
Clin. Cancer Res., April 1, 2003; 9(4): 1517 - 1527.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. L. Murray, M. E. Gillogly, D. Przepiorka, H. Brewer, N. K. Ibrahim, D. J. Booser, G. N. Hortobagyi, A. P. Kudelka, K. H. Grabstein, M. A. Cheever, et al.
Toxicity, Immunogenicity, and Induction of E75-specific Tumor-lytic CTLs by HER-2 Peptide E75 (369-377) Combined with Granulocyte Macrophage Colony-stimulating Factor in HLA-A2+ Patients with Metastatic Breast and Ovarian Cancer
Clin. Cancer Res., November 1, 2002; 8(11): 3407 - 3418.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. M. Krackhardt, M. Witzens, S. Harig, F. S. Hodi, A. J. Zauls, M. Chessia, P. Barrett, and J. G. Gribben
Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX
Blood, August 28, 2002; 100(6): 2123 - 2131.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. M. Krackhardt, S. Harig, M. Witzens, R. Broderick, P. Barrett, and J. G. Gribben
T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy
Blood, June 17, 2002; 100(1): 167 - 173.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. L. Disis, T. A. Gooley, K. Rinn, D. Davis, M. Piepkorn, M. A. Cheever, K. L. Knutson, and K. Schiffman
Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide-Based Vaccines
J. Clin. Oncol., June 1, 2002; 20(11): 2624 - 2632.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. Livingston, C. Crimi, M. Newman, Y. Higashimoto, E. Appella, J. Sidney, and A. Sette
A Rational Strategy to Design Multiepitope Immunogens Based on Multiple Th Lymphocyte Epitopes
J. Immunol., June 1, 2002; 168(11): 5499 - 5506.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. K. Roberts, P. O. Livingston, D. B. Agus, J. Pinilla-Ibarz, A. Zelenetz, and D. A. Scheinberg
Vaccination with CD20 peptides induces a biologically active, specific immune response in mice
Blood, May 15, 2002; 99(10): 3748 - 3755.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. A. Pilon, M. P. Piechocki, and W.-Z. Wei
Vaccination with Cytoplasmic ErbB-2 DNA Protects Mice from Mammary Tumor Growth Without Anti-ErbB-2 Antibody
J. Immunol., September 15, 2001; 167(6): 3201 - 3206.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Meyer zum Buschenfelde, J. Metzger, C. Hermann, N. Nicklisch, C. Peschel, and H. Bernhard
The Generation of Both T Killer and Th Cell Clones Specific for the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells
J. Immunol., August 1, 2001; 167(3): 1712 - 1719.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. L. Yip, G. Smith, J. Koch, S. Dubel, and R. L. Ward
Identification of Epitope Regions Recognized by Tumor Inhibitory and Stimulatory Anti-ErbB-2 Monoclonal Antibodies: Implications for Vaccine Design
J. Immunol., April 15, 2001; 166(8): 5271 - 5278.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Adris, E. Chuluyan, A. Bravo, M. Berenstein, S. Klein, M. Jasnis, C. Carbone, Y. Chernajovsky, and O. L. Podhajcer
Mice Vaccination with Interleukin 12-transduced Colon Cancer Cells Potentiates Rejection of Syngeneic Non-Organ-related Tumor Cells
Cancer Res., December 1, 2000; 60(23): 6696 - 6703.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
L. Qi, J.-M. Rojas, and S. Ostrand-Rosenberg
Tumor Cells Present MHC Class II-Restricted Nuclear and Mitochondrial Antigens and Are the Predominant Antigen Presenting Cells In Vivo
J. Immunol., November 15, 2000; 165(10): 5451 - 5461.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S.-A. Chen, M.-H. T. F.-T. Wu, A. Hsiang, Y.-L. Chen, H.-Y. Lei, T.-S. Tzai, H. W. C. Leung, Y.-T. Jin, C.-L. Hsieh, L.-H. Hwang, et al.
Induction of Antitumor Immunity with Combination of HER2/neu DNA Vaccine and Interleukin 2 Gene-modified Tumor Vaccine
Clin. Cancer Res., November 1, 2000; 6(11): 4381 - 4388.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. M. Hiltbold, A. M. Vlad, P. Ciborowski, S. C. Watkins, and O. J. Finn
The Mechanism of Unresponsiveness to Circulating Tumor Antigen MUC1 Is a Block in Intracellular Sorting and Processing by Dendritic Cells
J. Immunol., October 1, 2000; 165(7): 3730 - 3741.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Meyer zum Buschenfelde, N. Nicklisch, S. Rose-John, C. Peschel, and H. Bernhard
Generation of Tumor-Reactive CTL Against the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells Derived from CD34+ Hemopoietic Progenitor Cells
J. Immunol., October 1, 2000; 165(7): 4133 - 4140.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Kobayashi, M. Wood, Y. Song, E. Appella, and E. Celis
Defining Promiscuous MHC Class II Helper T-Cell Epitopes for the HER2/neu Tumor Antigen
Cancer Res., September 1, 2000; 60(18): 5228 - 5236.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
N. K. Dakappagari, D. B. Douglas, P. L. Triozzi, V. C. Stevens, and P. T. P. Kaumaya
Prevention of Mammary Tumors with a Chimeric HER-2 B-cell Epitope Peptide Vaccine
Cancer Res., July 1, 2000; 60(14): 3782 - 3789.
[Abstract] [Full Text]

Home page
 Am. J. Pathol.Home page
V. Visco, R. Bei, E. Moriconi, W. Gianni, M. H. Kraus, and R. Muraro
ErbB2 Immune Response in Breast Cancer Patients with Soluble Receptor Ectodomain
Am. J. Pathol., April 1, 2000; 156(4): 1417 - 1424.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Mateo, J. Gardner, Q. Chen, C. Schmidt, M. Down, S. L. Elliott, S. J. Pye, H. Firat, F. A. Lemonnier, J. Cebon, et al.
An HLA-A2 Polyepitope Vaccine for Melanoma Immunotherapy
J. Immunol., October 1, 1999; 163(7): 4058 - 4063.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. L. Disis, K. H. Grabstein, P. R. Sleath, and M. A. Cheever
Generation of Immunity to the HER-2/neu Oncogenic Protein in Patients with Breast and Ovarian Cancer Using a Peptide-based Vaccine
Clin. Cancer Res., June 1, 1999; 5(6): 1289 - 1297.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. A. Foon, J. Yannelli, and M. Bhattacharya-Chatterjee
Colorectal Cancer as a Model for Immunotherapy
Clin. Cancer Res., February 1, 1999; 5(2): 225 - 236.
[Full Text] [PDF]

Home page
 J. Exp. Med.Home page
A.-M. T. Ciupitu, M. Petersson, C. L. O'Donnell, K. Williams, S. Jindal, R. Kiessling, and R. M. Welsh
Immunization with a Lymphocytic Choriomeningitis Virus Peptide Mixed with Heat Shock Protein 70 Results in Protective Antiviral Immunity and Specific Cytotoxic T Lymphocytes
J. Exp. Med., March 2, 1998; 187(5): 685 - 691.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Osanto
Vaccine Trials for the Clinician: Prospects for Tumor Antigens
Oncologist, October 1, 1997; 2(5): 284 - 299.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.